Answers are grounded in this paper and cite their sources.
Rituximab is a treatment option in several SARDs. Upcoming trials, use in daily practice and the safety profile are elaborated on.
No takes yet. Share an insight, caveat, or question.
Berghen et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: